Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples